There is no evidence-based BPC-157 and TB-500 dosage for routine human recovery. No approved label establishes one, and published studies do not support copying a milligram schedule from a forum or vial seller. BPC-157 evidence is mostly animal research plus a few small human reports using routes unlike a routine subcutaneous injection. FDA reviewers found no study in which TB-500 itself was administered to humans. A defensible dose decision therefore starts with the exact compound, route, concentration, medical history, and prescriber—not a syringe number found online.
BPC-157 and TB-500 dosage in published evidence
The numbers in the literature describe experiments, not a protocol for a person to follow. Route and molecule matter as much as the number.
| Evidence | Reported exposure | What it can and cannot tell us |
|---|---|---|
| BPC-157, surgically transected Achilles tendon in rats | 10 micrograms, 10 nanograms, or 10 picograms per kilogram, injected into the abdomen once daily | Shows the wide dose range tested in one animal injury model; it does not establish a human dose |
| BPC-157, retrospective knee-pain charts | 2–4 mg placed inside the knee joint, one or two procedures | A small, uncontrolled human report using a clinician-administered joint injection, not routine subcutaneous dosing |
| BPC-157 plus full-length thymosin beta-4, four knee-pain charts | 2–4 mg BPC-157 plus 3–6 mg thymosin beta-4 inside the joint | Too small to compare doses, and thymosin beta-4 is not the same molecule as TB-500 |
| Recombinant full-length thymosin beta-4, phase I study in healthy adults | Single IV doses of 0.05–25 micrograms/kg; multiple IV doses of 0.5–5 micrograms/kg daily for 10 days | Safety and pharmacokinetic work on a different molecule and route, with no injury-recovery endpoint |
The rat Achilles study reported its dose by body weight and found differences from saline in healing measures (Sikiric et al., Journal of Orthopaedic Research 2003). Translating those figures into a fixed human milligram amount would ignore species, route, metabolism, and the surgically created injury model.
The human knee report was a chart review, not a randomized trial. Sixteen people were reached for follow-up; 12 had received BPC-157 alone and four had received BPC-157 plus full-length thymosin beta-4 (Lee and Padgett, Alternative Therapies in Health and Medicine 2021). FDA's 2026 evidence table records the BPC-157 range as 2–4 mg over one or two intra-articular procedures (FDA BPC-157 briefing). That is evidence that these amounts were used, not evidence of an optimal dose or a schedule for self-injection.
Why TB-500 is not interchangeable with thymosin beta-4
TB-500 is a synthetic, N-acetylated seven-amino-acid fragment corresponding to residues 17–23 of the 43-amino-acid thymosin beta-4 peptide. Articles and online dosing charts often shorten both names to “TB4,” hiding a real molecular difference.
That distinction changes how evidence should be read. A randomized phase I study gave full-length recombinant thymosin beta-4 intravenously to healthy volunteers and tracked safety and pharmacokinetics (Wang et al., Journal of Cellular and Molecular Medicine 2021). It did not study TB-500 or recovery from an injury. FDA's July 2026 review found no human study administering TB-500 and no clinical evidence establishing a wound-healing dose (FDA TB-500 briefing).
Why online milligram figures do not transfer
A rodent dose expressed per kilogram is not a human dosing chart. Simple multiplication by body weight misses differences in surface area, absorption, metabolism, injection route, formulation, and the endpoint being studied. The error becomes larger when a dose of full-length thymosin beta-4 is relabeled as TB-500 or when an intra-articular procedure is treated like a subcutaneous schedule.
The practical comparison is captured in BPC-157 versus TB-500: the compounds are related to different evidence bases, even when they appear together in recovery discussions. Published numbers can frame a prescriber's uncertainty. They cannot remove it.
How the Wolverine blend changes the decision
Promise's Wolverine blend combines BPC-157 and TB-500 at a pharmacy-set ratio. It is prescribed as one formulation. The reviewing provider therefore considers the intended clinical use, the fixed amount of each component per milliliter, other medications, relevant conditions, prior reactions, and a monitoring plan. Changing the volume changes both components together; it does not independently tune one peptide.
That is why a blend amount cannot be inferred from a BPC-157-only number or a full-length thymosin beta-4 study. The Wolverine peptide stack overview explains why the compounds are paired; this page stays with how the dose decision is bounded by the evidence.
Reconstitution volume is where syringe math breaks
Syringe units measure liquid volume, not peptide mass. On a U-100 insulin syringe, 100 units equals 1 mL. The amount of peptide represented by 10 units changes whenever the vial concentration changes.
The governing arithmetic is: concentration = peptide amount ÷ liquid volume, then peptide amount delivered = concentration × drawn volume. A hypothetical example shows why the unit mark alone is incomplete:
| Hypothetical vial | Liquid added | Concentration | 10 syringe units (0.1 mL) contains |
|---|---|---|---|
| 10 mg total peptide | 2 mL | 5 mg/mL | 0.5 mg |
| 10 mg total peptide | 4 mL | 2.5 mg/mL | 0.25 mg |
The same 10-unit mark produces a twofold difference. A switch in vial strength, blend ratio, or reconstitution volume can create the same problem. The pharmacy label and prescription define the intended concentration and amount; the table above is an arithmetic illustration, not a dosing recommendation. How peptide reconstitution works covers the concentration calculation in more detail.
Regulatory status and clinical accountability
BPC-157 and TB-500 have no approved U.S. drug labels. At Promise, the two are dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved.
On July 23, 2026, FDA advisers voted 8–6 with one abstention to recommend both substances for the 503A bulk-substances list (Associated Press, 2026). FDA explains that advisory committees give nonbinding recommendations; the vote did not complete rulemaking or create approved drug labels (FDA meeting record).
Regulatory status is one fact in a clinical decision, not a marketing gate. A licensed provider may still prescribe a compounded formulation, and that decision belongs to the patient and the doctor. At Promise, a licensed provider reviews every request and either prescribes or declines based on medical eligibility; not everyone qualifies.
What a prescriber can actually individualize
With no validated human schedule, the meaningful variables are the reason for treatment, route, formulation concentration, fixed blend ratio, health history, concurrent drugs, and what will be monitored. A prescriber also has to decide whether uncertainty in the evidence is acceptable for that individual.
The safest interpretation of any BPC-157 dosing chart or TB-500 dosage table is literal: it reports what one source used under one set of conditions. It does not become a personal dose until a prescriber relates the specific pharmacy formulation to a specific patient.